Working... Menu
Trial record 27 of 83 for:    PEELING SKIN SYNDROME

A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00349531
Recruitment Status : Completed
First Posted : July 7, 2006
Last Update Posted : May 21, 2012
Information provided by:
Boehringer Ingelheim

Brief Summary:
The primary objective of this study is to investigate the effects on RLS symptoms and sleep disturbance of pramipexole (Mirapexin) 0.125 mg/day to 0.75 mg/day per os for 12 weeks, compared to placebo, in the treatment of patients with idiopathic Restless Legs Syndrome

Condition or disease Intervention/treatment Phase
Restless Legs Syndrome Drug: Pramipexole Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 369 participants
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Official Title: A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/Day Per os for 12 Weeks to Investigate the Effects on RLS Symptoms (IRLS) and Sleep Disturbance (MOS Sleep Scale) in Out-patients With Idiopathic Restless Legs Syndrome
Study Start Date : July 2006
Actual Primary Completion Date : May 2007

Primary Outcome Measures :
  1. Primary endpoint: change from baseline after 12 weeks in IRLS total score. Co-primary endpoint: change from baseline after 12 weeks in MOS sleep disturbance score. [ Time Frame: 12 weeks after start of treatment ]

Secondary Outcome Measures :
  1. Secondary endpoints: CGI-I and IRLS responder rate other MOS dimensions, RLS-6 items 4-6, IRLS item 10, VAS ,Verbal Fluency Tests ,RLS-QoL scores PGI responder rate adverse event profile, systolic and diastolic blood pressure, pulse rate [ Time Frame: 12 weeks after start of treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Written informed consent consistent with ICH-GCP and local IRB/IEC requirements obtained prior to any study procedures being performed and the ability and willingness to comply with study treatment regimen and to attend study assessments.
  2. Male or female out-patients aged 18-80 years.
  3. Diagnosis of idiopathic RLS according to the clinical RLS criteria of the IRLSSG [P03-03355]. All four criteria must be present to fulfil the diagnosis of RLS:

    • An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs. (Sometimes the urge to move is present without the uncomfortable sensations and sometimes the arms or other body parts are involved in addition to the legs)
    • The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting
    • The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues
    • The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night. (When symptoms are very severe, the worsening at night may not be noticeable but must have been previously present).
  4. RLS symptoms present at least 2 to 3 days per week during the last 3 months prior to baseline (Visit 2).
  5. IRLS total score >15 at baseline (Visit 2).

Exclusion Criteria:

  1. Women of child-bearing potential who do not use during the trial an adequate method of contraception.
  2. Women of child-bearing potential not having negative pregnancy test at screening.
  3. Breastfeeding women.
  4. Concomitant or previous pharmacologic therapy for RLS with: dopamine agonists or levodopa (within 14 days prior to baseline), levodopa with augmentation, unsuccessful prior treatment with non-ergot dopamine agonists.
  5. All treatment less than 14 days or concomitant treatment with medication or dietary supplements which could significantly influence RLS symptoms.
  6. Withdrawal symptoms.
  7. Pramipexole non-responders in other indications than RLS.
  8. Patients with known hypersensitivity to pramipexole or any other component of the investigational product or placebo tablets.
  9. Diabetes mellitus requiring insulin therapy.
  10. Any of the following laboratory results at screening:

    • any clinically significant abnormalities in laboratory parameters;
    • haemoglobin below LLN.
  11. Clinically significant renal disease or calculated creatinine clearance lower than 30 mL/minute.
  12. Clinically significant hepatic disease or GPT >2 times the ULN.
  13. Serum ferritin <10 ng/mL.
  14. History of/or malignant melanoma.
  15. History of/or clinically significant vision abnormalities.
  16. History of/or any other sleep disorder (other than RLS-related).
  17. History of/or major depressive disorder or any psychotic disorder, mental disorders or any present Axis I psychiatric disorder according to DSM IV requiring any medical therapy.
  18. History of/or clinical signs of suicidal behaviour, suicide ideation or acute suicidal tendency according to the investigator's opinion.
  19. History of/or alcohol abuse or drug addiction (within 2 years).
  20. Patients on a shift-work-schedule or who are otherwise unable to follow a regular sleep-wake cycle.
  21. Participation in an investigational drug study within one month.
  22. Any clinically significant conditions that would interfere or constitute a health hazard for the patient.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00349531

  Show 49 Study Locations
Sponsors and Collaborators
Boehringer Ingelheim
Layout table for investigator information
Study Chair: Boehringer Ingelheim Boehringer Ingelheim

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim Identifier: NCT00349531     History of Changes
Other Study ID Numbers: 248.615
First Posted: July 7, 2006    Key Record Dates
Last Update Posted: May 21, 2012
Last Verified: May 2012

Additional relevant MeSH terms:
Layout table for MeSH terms
Restless Legs Syndrome
Psychomotor Agitation
Sleep Wake Disorders
Pathologic Processes
Neurologic Manifestations
Nervous System Diseases
Psychomotor Disorders
Neurobehavioral Manifestations
Signs and Symptoms
Sleep Disorders, Intrinsic
Mental Disorders
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents